• 18.10.2018 – 07:01

  UCB Pharma

  UCB Accelerates Anti-FcRn Rozanolixizumab in Myasthenia Gravis Into Confirmatory Development Phase

  Brussels (ots/PRNewswire) - - Positive outcomes in proof-of-concept study with subcutaneous rozanolixizumab in patients with myasthenia gravis (MG): clinically meaningful improvement in multiple disease-related endpoints - Strong 68% mean reduction of Serum IgG and IgG Autoantibodies observed - Safety profile ...

• 11.10.2018 – 12:57

  Janssen Pharmaceutica

  Janssen to highlight data from broad rheumatology portfolio at the 2018 Annual meeting of the American College of Rheumatology

  Beerse, Belgium (ots/PRNewswire) - - One-year results from the Phase 2 study evaluating STELARA® (ustekinumab) in patients with active systemic lupus erythematosus featured in a plenary presentation - 13 presentations from approved and pipeline products provide real-world treatment and disease insights across ...

• 28.08.2018 – 13:36

  Grünenthal Group

  Duzallo®, a fixed-dose combination therapy for gout, approved in Europe

  Aachen (ots) - Today, Grünenthal announced that the European Commission has followed the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) and granted Duzallo® marketing authorization for the EU/EEA. Duzallo® is a fixed-dose combination (FDC) therapy that combines allopurinol and lesinurad. It is indicated for the treatment of ...

• 29.06.2018 – 01:02

  Astellas Pharma Europe Limited

  Results From Pivotal Phase 3 PROSPER Trial of XTANDI[TM] (enzalutamide) in Men With Non-Metastatic Castration-Resistant Prostate Cancer Published in New England Journal of Medicine

  Tokyo (ots/PRNewswire) - Results show enzalutamide plus androgen deprivation therapy significantly reduced the risk of developing metastases or death by 71 percent compared to placebo plus androgen deprivation therapy[i] FOR EMEA MEDICAL MEDIA ONLY - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji ...